CN113603713A - Preparation method and crystal form of substituted boric acid ester compound - Google Patents
Preparation method and crystal form of substituted boric acid ester compound Download PDFInfo
- Publication number
- CN113603713A CN113603713A CN202110844510.7A CN202110844510A CN113603713A CN 113603713 A CN113603713 A CN 113603713A CN 202110844510 A CN202110844510 A CN 202110844510A CN 113603713 A CN113603713 A CN 113603713A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- cancer
- crystalline form
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 20
- -1 boric acid ester compound Chemical class 0.000 title description 21
- 239000013078 crystal Substances 0.000 title description 21
- 239000004327 boric acid Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 288
- 238000000034 method Methods 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims abstract description 18
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 84
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 75
- 239000002904 solvent Substances 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 18
- 230000005855 radiation Effects 0.000 claims description 18
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 16
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 16
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 11
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 10
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 10
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000017497 prostate disease Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 5
- 229940011051 isopropyl acetate Drugs 0.000 claims description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 5
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 5
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- 235000002639 sodium chloride Nutrition 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 230000008569 process Effects 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 229940079156 Proteasome inhibitor Drugs 0.000 description 16
- 239000003207 proteasome inhibitor Substances 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000001853 liver microsome Anatomy 0.000 description 10
- 229960001592 paclitaxel Drugs 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical group ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000012265 solid product Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- 239000012317 TBTU Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012320 chlorinating reagent Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 208000009527 Refractory anemia Diseases 0.000 description 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000012026 peptide coupling reagents Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 229960003648 ixazomib Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-DICFDUPASA-N 2-amino-2,2-dideuterioacetic acid Chemical compound [2H]C([2H])(N)C(O)=O DHMQDGOQFOQNFH-DICFDUPASA-N 0.000 description 2
- ZAZPDOYUCVFPOI-UHFFFAOYSA-N 2-methylpropylboronic acid Chemical group CC(C)CB(O)O ZAZPDOYUCVFPOI-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000005461 Canertinib Substances 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 description 2
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 2
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 150000001722 carbon compounds Chemical class 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N epoxyketone group Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229960005399 satraplatin Drugs 0.000 description 2
- 190014017285 satraplatin Chemical compound 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 2
- 229960000922 vinflunine Drugs 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FWFGIHPGRQZWIW-SQNIBIBYSA-N (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-phenylacetic acid cyclopentyl ester Chemical compound O=C([C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)C=1C=CC=CC=1)OC1CCCC1 FWFGIHPGRQZWIW-SQNIBIBYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182780 Polyphenon E Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000012500 ion exchange media Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229940000764 kyprolis Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940030115 ninlaro Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010006260 pegylated granulocyte colony-stimulating factor Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical class [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses(A) The invention also discloses a pharmaceutical composition containing the compound shown as the formula (A) and a method for treating diseases related to proteasome by using the composition.
Description
The application is a divisional application of an invention patent application with the application date of 2018, 11 and 21, and the application number of 201811390368.8, and the invention name of the invention is 'a preparation method of a substituted borate compound and a crystal form of the compound'.
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a high-purity substituted borate compound, a preparation method and a crystal form thereof.
Background
Proteasomes (proteasomes) are bulky multivalent complex enzymes that are involved in many important physiological and biochemical processes in cells, such as DNA repair, cell cycle operation, signaling, antigen presentation, transmembrane localization of proteins, etc., and play a major role in balancing important intracellular enzymes. The function of the proteasome is achieved through the ubiquitin-proteasome pathway (UPP). UPP not only catalyzes and degrades abnormal proteins, but also participates in many regulation and protein renewal and processing processes. The catalytic processes of these proteins are involved in important biochemical mechanisms in the pathogenesis of human diseases.
The proteasome inhibitor (proteasome inhibitor) further influences the expression of cell growth related protein, cell factors and signal molecules by inhibiting the activity of proteasome, interferes the original proliferation, differentiation and apoptosis processes of cells, and has more obvious inhibition on the growth of tumor cells.
Proteasome inhibitors are mainly peptide aldehydes, peptide boronic acids, peptide epoxy ketones, peptide vinyl sulfones, beta lactones and other compounds. The peptide boronic acid proteasome inhibitor Bortezomib (Bortezomib, trade name VELCADE) was the first proteasome inhibitor to be used clinically and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) in 2003 and 2006, respectively. The peptide epoxyketone peptide proteasome inhibitor Carfilzomib (trade name Kyprolis) is approved by FDA for treating multiple myeloma in 2012, and becomes a second proteasome antitumor drug on the market. The peptide boronic acid proteasome inhibitor, epsiprole (Ninlaro) was approved by the FDA for the treatment of multiple myeloma in 2015, and became the second peptide boronic acid proteasome inhibitor to be marketed. Peptide backbone proteasome inhibitors such as marketed drugs and reported boronic acid proteasome inhibitors, e.g., WO2005/021558, WO2005/016859, WO2006/086600, WO2009/02044, WO2010/012222, WO2011/109355, WO2011/026349, WO2011/087822, WO2013/092979, have low in vivo stability, too short half-life in plasma, and fast clearance (Miller et al.j Med Chem, 2015, 58: 2036-41).
Therefore, there is still a need in the art to develop proteasome inhibitors that have inhibitory activity or better pharmacodynamic properties for the proteasome.
Disclosure of Invention
In one aspect, the present invention relates to a process for preparing a compound of formula (a) or a crystalline form thereof:
wherein n and m are independently selected from 0 or 1; and n and m are different from each other,
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a):
b) optionally crystallizing the compound of formula (a).
In another aspect, the present invention relates to a compound of formula (a-1), or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention also relates to a crystalline compound of formula (A-1),
characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163 ° 2θ±0.2θ2θBy using Cu-Ka radiation on a diffractometerThe wavelength of (2) is measured.
In another aspect, the present invention provides a crystalline compound of formula (A-2),
characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578,17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840 ° 2θ±0.2θ2θBy using Cu-Ka radiation on a diffractometerThe wavelength of (2) is measured.
In another aspect, the present invention provides a method for preparing the pharmaceutical composition as described above, comprising the steps of: a pharmaceutically acceptable excipient is mixed with a compound of the present invention, or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, to form a pharmaceutical composition.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable excipient. In a specific embodiment, the compounds of the present invention are provided in an effective amount in the pharmaceutical composition. In particular embodiments, the compounds of the present invention are provided in a therapeutically effective amount. In particular embodiments, the compounds of the present invention are provided in a prophylactically effective amount. In another embodiment, the pharmaceutical composition is an injection, a sachet, a tablet, a pill, a powder or a granule. In another embodiment, the pharmaceutical composition further comprises an additional therapeutic agent, wherein the additional therapeutic agent is an agent for cancer, cardiovascular disease, inflammation, immunological disease, kidney disease, angiogenesis, or prostate disease.
In another aspect, there is provided the use of a compound as described in the first aspect of the invention, or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the inhibition of proteasome. In another embodiment, the compounds can be used for the treatment and prevention of diseases associated with proteasome targets. In another embodiment, the pharmaceutical composition is used for the treatment and prevention of the following diseases: cancer, cardiovascular disease, inflammation, immunological disease, nephropathy, angiogenesis, or prostate disease. Preferably, the cancer includes, but is not limited to: multiple myeloma, non-small cell lung cancer, uterine cancer, rectum cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumor, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
In another aspect, the present invention provides a method of treatment comprising the steps of: administering a compound described herein, or a crystalline form, a pharmaceutically acceptable hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein, to a subject in need of treatment, thereby inhibiting the proteasome. Preferably, the disease comprises: cancer, cardiovascular disease, inflammation, immunological disease, nephropathy, angiogenesis or prostate disease. Preferably, the cancer includes, but is not limited to: multiple myeloma, non-small cell lung cancer, uterine cancer, rectum cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumor, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
Detailed Description
In one aspect, the present invention relates to a process for preparing a compound of formula (a) or a crystalline form thereof:
wherein n and m are independently selected from 0 or 1; and n and m are different from each other,
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a):
b) optionally crystallizing the compound of formula (a).
In another aspect, the present invention relates to a process for preparing a compound of formula (a-1) or a crystalline form thereof:
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a-1), wherein the solvent is dioxane:
b) optionally crystallizing the compound of formula (A-1).
Preferably, wherein the solvent of step a) is 1, 4-dioxane.
Preferably, wherein the reaction temperature of step a) is from 40 ℃ to the boiling temperature of dioxane (101.1 ℃), preferably from 40 ℃ to 80 ℃.
Preferably, wherein the reaction temperature of step a) is 80 ℃.
Preferably, wherein step a) is adding the compound of formula (B) and citric acid to a solvent, the reaction is stirred at 80 ℃ until the starting materials react completely.
Preferably, step b) wherein the solvent of step a) is removed, ethyl acetate is added at room temperature and stirred until a solid precipitates.
Preferably, in step b), ethyl acetate is added at room temperature and stirred for 12h, solid is precipitated and filtered by suction.
In another aspect, the present invention relates to a process for preparing a compound of formula (a-2) or a crystalline form thereof:
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a-2), wherein the solvent is selected from the group consisting of methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, methyl tert-butyl ether, and mixtures thereof:
b) optionally crystallizing the compound of formula (A-2).
Preferably, wherein the reaction temperature of step a) is from 40 ℃ to the boiling temperature of the solvent, preferably from 40 ℃ to e.g. 80 ℃.
Preferably, the step a) is that the compound of the formula (B) and citric acid are added into a solvent, and the reaction is stirred until the reaction of the raw materials is completed.
Preferably, step b) wherein the solvent of step a) is removed, ethyl acetate is added at room temperature and stirred until a solid precipitates.
Preferably, wherein the solvent of step a) is ethyl acetate.
Preferably, wherein the reaction temperature of step a) is 70 ℃.
Preferably, the compound of formula (B) and citric acid are added into the solvent, stirred and reacted for 10 minutes at 70 ℃, cooled to room temperature and stirred until solid is precipitated.
Preferably, the temperature is reduced to room temperature, the mixture is stirred for 12 hours, solid is separated out, and the mixture is filtered by suction.
In another aspect, the present invention relates to a compound of formula (a) or a crystal thereof prepared by any one of the above-described methods.
In another aspect, the present invention relates to a compound of formula (A-1), or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof
In another aspect, the present invention relates to the compound of formula (A-1) in crystalline form I,
characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 16.137, 17.56, 19.001, 20.201, 24.88 and 25.358 degree2 theta + -0.2 DEG 2 theta, using a wavelength on a diffractometer ofCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-1) crystalline form I, characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.599, 14.80, 16.137, 17.56, 19.001, 20.201, 21.02, 24.88, 25.358 DEG 2 theta +/-0.2 DEG 2 theta, which is used on a diffractometer at a wavelength ofCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-1) crystalline form I, characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-1) crystalline form I, wherein the diffractogram is substantially as shown in figure 1.
In another aspect, the present invention is directed to compound of formula (a-1) form I characterized by a Differential Scanning Calorimetry (DSC) curve that comprises an endotherm at about 197.9 ℃ and about 249.7 ℃.
In another aspect, the present invention relates to the compound of formula (a-1) in crystalline form I, wherein said DSC curve is substantially as shown in figure 2.
In another aspect, the present invention relates to the compound of formula (A-2) in crystalline form I,
it is characterized in thatThe X-ray powder diffraction pattern includes the following peaks: 5.740, 7.517, 11.458, 19.438, 19.801 and 22.262 DEG 2 theta + -0.2 DEG 2 theta, using a wavelength on a diffractometerCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-2) crystalline form I, characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.740, 7.517, 11.458, 12.439, 16.578, 19.438, 19.801, 22.262, and 22.999 ° 2 θ ± 0.2 ° 2 θ, using a wavelength on a diffractometerCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-2) crystalline form I, characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1).
In another aspect, the present invention relates to compound of formula (a-2) crystalline form I, wherein the diffractogram is substantially as shown in figure 3.
In another aspect, the present invention is directed to compound of formula (a-2) form I characterized by a Differential Scanning Calorimetry (DSC) curve that comprises endotherms at about 224.6 ℃, about 237.0 ℃, and about 253.5 ℃.
In another aspect, the present invention relates to the compound of formula (a-2) in crystalline form I, wherein said DSC curve is substantially as shown in figure 4.
In another aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (a) or crystals thereof, or compound form I of formula (a-1) or compound form I of formula (a-2), prepared by a preparation process as described herein.
In another aspect, the present invention relates to the use of the compound of formula (a) or its crystal prepared by the preparation method of the present invention, or the compound of formula (a-1) in the form of crystal form I or the compound of formula (a-2) in the preparation of a medicament for treating and preventing proteasome related diseases.
In another aspect, the present invention relates to the use of the compound of formula (a) or its crystal, or the compound of formula (a-1) in crystal form I, or the compound of formula (a-2) in crystal form I, prepared by the preparation method of the present invention, in the preparation of a medicament for the treatment and prevention of cancer, cardiovascular disease, inflammation, immunological disease, nephropathy, angiogenesis or prostate disease.
In a further aspect, the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, rectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumor, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
Drawings
Figure 1 shows the X-ray powder diffraction (XRPD) of compound form I of formula (a-1).
FIG. 2 shows a Differential Scanning Calorimeter (DSC) curve and a thermogravimetric analysis (TGA) curve of the crystalline form I of the compound of formula (A-1).
Figure 3 shows the X-ray powder diffraction (XRPD) of compound form I of formula (a-2).
FIG. 4 shows a Differential Scanning Calorimeter (DSC) curve and a thermogravimetric analysis (TGA) curve of the crystalline form I of the compound of formula (A-2).
Detailed Description
Definitions and abbreviations
Herein, "deuterated", unless otherwise specified, means that one or more hydrogens of a compound or group are replaced with deuterium; deuterium can be mono-, di-, poly-, or fully substituted. The terms "deuterated one or more" and "deuterated one or more" are used interchangeably.
Herein, unless otherwise specified, the deuterium isotope content of deuterium at the deuterium substitution position is at least 0.015% more, preferably more than 30%, more preferably more than 50%, more preferably more than 75%, more preferably more than 95%, more preferably more than 99% more than the natural deuterium isotope content.
Herein, unless otherwise specified, "non-deuterated compound" means a compound containing deuterium at an atomic ratio of deuterium not higher than the natural deuterium isotope content (0.015%).
As used herein, the term "independently selected" means that the plurality of groups are each selected from certain substituents and there is no interconnection between each group, e.g., "m, n are independently selected from 0 or 1", meaning that m is selected from 0 or 1, n is selected from 0 and 1, and m and n are not interconnected.
As used herein, the term "compounds of the present invention" refers to compounds of formula (I). The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compounds of formula (I).
The term "pharmaceutically acceptable salts" refers, inter alia, to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, the pharmaceutically acceptable salts are described in detail by Berge et al in J.pharmaceutical Sciences (1977)66: 1-19. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Salts formed using methods conventional in the art, e.g., ion exchange methods, are also included. Other pharmaceutically acceptable salts include: adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cypionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactylate, dihydrogenated iodate, and mixtures thereofAcid salts, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts derived from suitable bases include alkali metals, alkaline earth metals, ammonium and N+(C1-4Alkyl radical)4And (3) salt. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium salts, and the like. Other pharmaceutically acceptable salts include, if appropriate, non-toxic ammonium, quaternary ammonium and amine cations formed with counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
The term "solvate" refers to a complex of a compound of the present invention coordinated to solvent molecules in a specific ratio. "hydrate" refers to a complex formed by coordination of a compound of the present invention with water.
The invention also includes isotopically-labeled compounds, equivalent to those disclosed herein as the original compound. Examples of isotopes that can be listed as compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, respectively2H,3H,13C,14C,15N,17O,18O,31P,32P,35S,18F and36and (4) Cl. The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, wherein isotopes or other isotopic atoms containing such compounds are within the scope of the present invention. Certain isotopically-labelled compounds of the invention, e.g.3H and14among these, the radioactive isotope of C is useful in tissue distribution experiments of drugs and substrates. Tritium, i.e.3H and carbon-14, i.e.14C, their preparation and examinationThe detection is easier and is the first choice among isotopes. Isotopically labeled compounds can be prepared by conventional methods by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents using the protocols set forth in the examples.
Abbreviations
EDC: 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide
HOBT: 1-hydroxybenzotriazoles
TBTU: O-benzotriazole-N, N, N ', N' -tetramethyluronium tetrafluoroborate
DCC: dicyclohexylcarbodiimide
HBTU: O-benzotriazole-N, N, N ', N' -tetramethyluronium hexafluorophosphate
HCTU: 6-chlorobenzotriazole-1, 1,3, 3-tetramethylurea hexafluorophosphate
TCTU: o- (6-chlorobenzotriazol-1-yl) -1,1,3,3-N, N' -tetramethyluronium tetrafluoroborate HATU: 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethylurea hexafluorophosphate
PyBOP: benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
NMM: n-methylmorpholine
NEA: triethylamine
DIPEA: n, N-diisopropylethylamine
PCl3: phosphorus trichloride
PCl5: phosphorus pentachloride
NaOH: sodium hydroxide
KOH: potassium hydroxide
Preparation method
The methods of the present invention may be carried out using the methods disclosed herein and conventional modifications thereof, which will be apparent from the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to those taught herein. The synthesis of typical compounds described herein, for example, formula (A-1) and formula (A-2), can be accomplished as described in the examples below.
Typical embodiments of the compounds according to the invention may be synthesized using the general reaction schemes described below. It will be apparent from the description herein that the general scheme can be modified by substituting starting materials with other materials having similar structures to produce correspondingly different products. Given the desired product in which the substituents are defined, the desired starting material can generally be determined by inspection. The starting materials are typically obtained from commercial sources or synthesized using published methods. To synthesize a compound of the disclosed embodiments, examining the structure of the compound to be synthesized will provide for the identification of each substituent. In view of the examples herein, the properties of the final product will typically reveal the characteristics of the desired starting materials by a simple inspection process.
The compounds of the present disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It is to be understood that where typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions may also be used unless otherwise indicated. Optimal reaction conditions may vary with the particular reactants or solvents used, but can be determined by one skilled in the art by routine optimization procedures.
In addition, the compounds of the present disclosure may contain one or more chiral centers. Thus, if desired, the compounds may be prepared as pure stereoisomers or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomerically enriched mixtures. Unless otherwise indicated, all such stereoisomers (as well as enriched mixtures) are included within the scope of the present invention. Pure stereoisomers (or enriched mixtures) can be prepared using, for example, optional active starting materials or stereoselective reagents well known in the art. Alternatively, racemic mixtures of the compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
The starting materials for the following reactions are generally known compounds or can be prepared by known methods or obvious modifications thereof. For example, many starting materials are available from commercial suppliers such as Shanghai Tebo chemical science and technology, Inc. (Shanghai, China),Saen chemical technology (shanghai) limited (shanghai, china), shanghai kupu chemical technology limited (shanghai, china), shanghai jin lu medical technology limited (shanghai, china), sandin biomedical limited (china), tianjin mosi medical technology limited (china tianjin), hunan, and zhongji medical technology limited (china hunan). Other Compounds can be prepared by procedures described in standard references or obvious modifications thereof, e.g., Fieser and Fieser's Reagents for Organic Synthesis (John Wiley and Sons,1991), Rodd's Chemistry of Carbon Compounds (Elsevier Science Publishers,1989), Organic Reactions (John Wiley and Sons,1991), March's Advanced Organic Chemistry (John Wiley and Sons, 5)thEdition,2001) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
In each of the exemplary embodiments, it may be advantageous to separate the reaction products from each other and/or from the starting materials. The desired product of each step or series of steps is isolated and/or purified (hereinafter referred to as isolated) to the desired degree of homogeneity by techniques common in the art. Typically, such separation involves heterogeneous extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography may include any number of methods, including, for example: reverse phase and normal phase chromatography; size exclusion chromatography; ion exchange chromatography; high, medium and low pressure liquid chromatography and equipment; small scale analytical chromatography; simulated Moving Bed (SMB) and preparative thin or thick layer chromatography, as well as small scale thin layer and flash chromatography techniques.
Another type of separation process involves treating the mixture with a reagent selected to bind to or separate from the product, unreacted starting materials, reaction byproducts, etc. Such agents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, and the like. Alternatively, the reagent may be an acid (in the case of a basic substance), a base (in the case of an acidic substance), a binding reagent such as an antibody, a binding protein, a selective chelating agent such as a crown ether, a liquid/liquid extraction reagent (LIX), or the like.
The choice of an appropriate separation method depends on the nature of the substances involved. For example, boiling point and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in heterogeneous extraction, and the like. Those skilled in the art will apply the techniques most likely to achieve the desired separation.
Single stereoisomers, e.g. enantiomers, substantially free of their stereoisomers, may be obtained by resolution of exo-racemic mixtures using, for example, methods for forming diastereomers using optically active resolving agents (Stereochemistry of Carbon Compounds, (1962), E.L.Eliel, McGraw Hill; Lochmuller, C.H., (1975) J.Chromatogr.,113 (3) 283-. The racemic mixture of chiral compounds of the present invention can be separated and resolved by any suitable method, including: (1) ionic diastereoisomeric salts with chiral compounds and separation by fractional crystallization or other methods; (2) forming a diastereomeric compound with a chiral derivatizing agent, separating the diastereomers, and converting to the pure stereoisomers; and (3) separating the substantially pure or enriched stereoisomers directly under chiral conditions.
As noted above, the present disclosure provides, in some embodiments, methods of preparing compounds of formula (a). In one embodiment, the present invention provides a process for the preparation of said compound of formula (A) or a crystalline form thereof,
wherein n and m are independently selected from 0 or 1; and n and m are different from each other,
the method comprises the following steps:
a) combining a compound of formula B with citric acid to form a compound of formula a:
wherein n and m are independently selected from 0 or 1; and n and m are different.
b) Optionally crystallizing the compound of formula (a).
In some embodiments, the reaction conditions of step a) comprise a solvent, preferably a solvent selected from the group consisting of methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dioxane, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, tert-butyl methyl ether, and mixtures thereof; more preferably, the solvent is dioxane; more preferably, the solvent is ethyl acetate.
In some embodiments, the reaction conditions of step a) include conducting at a temperature of from about 40 ℃ to about the boiling temperature of the solvent (preferably from about 40 ℃ to about 80 ℃); more optionally, the temperature is about 80 ℃; more preferably, the temperature is 70 ℃.
The applicants have surprisingly found that it is difficult to form the compound of formula (a-1) according to the prior art methods for the deuterated compounds of the invention (compounds of formula (B)). For example, by referring to the method of WO2009154737A1 (e.g., [0314] and [0318], using ethyl acetate as a solvent), after the completion of the addition at 74 ℃, either the reaction solution is cooled uncontrollably or slowly at a rate of 0.33 ℃/min to about 60 ℃ and reacted for 3 hours, and then cooled at a rate of 0.12 ℃/min to 25 ℃, only the compound of formula (A-2) can be obtained. Moreover, the Applicant has tried a variety of other solvents, all of which also give compounds of formula (A-2).
Thus, in some embodiments, when the reaction solvent of step a) is selected from the group consisting of methyl isobutyl ketone, acetone, acetonitrile, 2-methyl tetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, tert-butyl methyl ether, and mixtures thereof, the compound of formula (B) is reacted with citric acid to form the compound of formula (a-2).
In other embodiments, applicants have unexpectedly found that when the reaction solvent of step a) is dioxane (e.g., 1,4-dioxane), the compound of formula (B) reacts with citric acid to form the compound of formula (a-1).
In some embodiments, the above-described process for preparing a compound of formula (a) or a crystalline form thereof of the present invention further comprises the steps of:
c) combining a compound of formula C with a deprotection agent to form a compound of formula B:
in some embodiments, the reaction conditions of step c) comprise an organoboron reagent; preferably, the organoboron reagent is isobutyl boronic acid.
In some embodiments, the reaction conditions of step c) include a lower alkanol; preferably, the lower alkanol is selected from methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol or pentanol; more preferably, the lower alkanol is methanol.
In some embodiments, the reaction conditions of step c) include aqueous mineral acid; preferably, the inorganic acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid; more preferably, the mineral acid is selected from hydrochloric acid.
In some embodiments, the above-described process for preparing a compound of formula (a) or a crystalline form thereof of the present invention further comprises the steps of:
d) combining a compound of formula E with a compound of formula D to form a compound of formula C:
in some embodiments, the reaction conditions of step d) comprise a peptide coupling reagent; preferably, the peptide coupling reagent is selected from EDC and HOBT, TBTU, DCC and HOBT, HBTU, HCTU, TCTU, HATU or PyBOP; more preferably, the peptide coupling reagent is selected from TBTU, HBTU, HCTU, TCTU, HATU; most preferably, the peptide coupling reagent is TBTU.
In some embodiments, the reaction conditions of step d) comprise a base; preferably, the base is selected from NMM, TEA and DIPEA; more preferably, the base is selected from DIPEA.
In some embodiments, the reaction conditions of step d) comprise a solvent; preferably, the solvent is selected from dichloromethane, tetrahydrofuran, toluene, benzene, acetonitrile, dioxane and N, N-dimethylformamide, or a mixture thereof; more preferably, the solvent is selected from N, N-dimethylformamide.
In some embodiments, the reaction conditions of step d) comprise conducting at a temperature of about-20 ℃ to about 50 ℃; preferably, the temperature is selected from about-20 ℃ to about 10 ℃; more preferably, the temperature is 0 ℃.
In some embodiments, the above-described process for preparing a compound of formula (a) or a crystalline form thereof of the present invention further comprises the steps of:
e) reacting a compound of formula F with glycine-2, 2-d2Combining to form a compound of formula E:
in some embodiments, the reaction conditions of step e) comprise a base; preferably, the base is selected from NaOH and KOH; more preferably, the base is NaOH.
In some embodiments, the reaction conditions of step e) comprise a solvent; preferably, the solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran, acetone, DMF and DMSO; more preferably, the solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran and DMF; most preferably, the solvent is selected from tetrahydrofuran.
In some embodiments, the above-described process for preparing a compound of formula (a) or a crystalline form thereof of the present invention further comprises the steps of:
f) combining a compound of formula G with a chlorinating agent to form a compound of formula F:
in some embodiments, the reaction conditions of step f) comprise a chlorinating agent; preferably, the chlorinating agent is selected from thionyl chloride, oxalyl chloride, PCl with or without DMF3Or PCl5(ii) a More preferablyThe chlorinating agent is selected from thionyl chloride or oxalyl chloride; most preferably, the chlorinating agent is selected from thionyl chloride.
Crystal form
The present invention provides crystalline forms of the compound of formula (A-1) and the compound of formula (A-2) as defined herein.
Crystalline form I of the compound of formula (A-1) characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163 ° 2θ±0.2θ2θUsing Cu-Kalpha radiation in a diffractometerThe wavelength of (2) is measured. The compound of formula (a-1) crystalline form I is further characterized by a full (full) X-ray powder diffraction pattern substantially as shown in figure 1.
In some embodiments, form I of compound of formula (a-1) is characterized by a Differential Scanning Calorimetry (DSC) curve that comprises an endotherm at about 197.9 ℃, and an endotherm at about 249.7 ℃. The compound of formula (a-1) form I is further characterized by a DSC profile substantially as shown in figure 2.
Crystalline form I of the compound of formula (A-2) characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840 ° 2θ±0.2θ2θUsing Cu-Kalpha radiation in a diffractometerThe wavelength of (2) is measured. The compound of formula (a-2) crystalline form I is further characterized by a full (full) X-ray powder diffraction pattern substantially as shown in figure 3.
In some embodiments, form I of compound of formula (a-2) is characterized by a Differential Scanning Calorimetry (DSC) curve that comprises an endotherm at about 224.6 ℃ and 237.0 ℃, and an endotherm at about 253.5 ℃. The compound of formula (a-2) form I is further characterized by a DSC profile substantially as shown in figure 4.
Pharmaceutical compositions and methods of administration
The compound of the present invention and various crystal forms, pharmaceutically acceptable hydrates or solvates thereof, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the compound as a main active ingredient can be used for treating, preventing, and alleviating proteasome-mediated diseases, because the compound of the present invention has excellent inhibitory activity against proteasomes. According to the prior art, the compounds of the invention are useful for the treatment of the following diseases: cancer, cardiovascular disease, obesity, diabetes, and the like.
The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-200mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of being blended with and between the compounds of the present invention without significantly diminishing the efficacy of the compounds.
The terms "carrier," "excipient," or "carrier" are used interchangeably herein and include any and all solvents, diluents, and other liquid carriers, dispersing or suspending aids, surfactants, pH adjusters, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as appropriate for the particular dosage form desired. Unless any conventional carrier medium is incompatible with the compounds of the present invention, such as by producing any undesirable biological effect or interacting with any other component of the pharmaceutical composition to render the compound less effective or ineffective, or to produce a deleterious substance, its use is considered to be within the scope of the present invention.
Pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, carbonates, magnesium hydroxide and aluminum glycine, sorbic acid or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium phosphate, disodium hydrogen phosphate, sodium and zinc chlorides, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, polyethylene-polyoxypropylene block polymers, lanolin, sugars such as lactose, glucose, sucrose and mannitol, starches such as corn starch and potato starch, celluloses and derivatives thereof such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate, powdered tragacanth: malt, gelatin, talc, excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil, glycols such as propylene glycol and polyethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, alginic acid, isotonic saline, complex sodium chloride injection, alcohols such as ethanol, isopropanol, cetyl alcohol and glycerol, cyclodextrins such as hydroxypropyl β -cyclodextrin and sulfobutyl ether β -cyclodextrin, lubricants such as occasionally forgetting and magnesium stearate, petroleum spirits such as mineral oil and petrolatum. Coloring agents, mold release agents, coating agents, sweetening and flavoring agents, and perfuming agents, preservatives and antioxidants can also be present in the composition according to the judgment of the formulator.
The pharmaceutical compositions of the present invention may be prepared by methods well known in the art, such as conventional granulation, mixing, dissolution, encapsulation, lyophilization or emulsification methods and the like. The compositions may be manufactured in a variety of forms including granules, pellets or granules, powders, including freeze-dried, spin-dried or spray-dried powders, amorphous powders, tablets, capsules, syrups, suppositories, injections, emulsions, elixirs, suspensions or solutions.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited and, according to a preferred embodiment, the compositions of the present invention are formulated for pharmaceutical administration to a mammal, preferably a human. These pharmaceutical compositions of the invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implantable kit. The term "parenteral administration" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intravenously or subcutaneously. The formulations of the present invention may be designed to be short acting, fast releasing or long acting. In addition, the compounds may be administered locally rather than systemically, e.g., at the tumor site (e.g., by injection).
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, cyclodextrins, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters, sorbitan and mixtures thereof. In addition to inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, rotating and flavoring agents.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or solubilizers, for example, starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) lubricants, for example, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a parenterally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Acceptable carriers and solvents that may be used are water, compound sodium chloride injection, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium, and any bland fixed oil may be employed, including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Injectable agents can be sterilized, for example, by filtration through bacterial traps or by incorporating sterilizing agents in the form of sterile solid compositions which are dissolved or dispersed in sterile water or other sterile injectable medium prior to use. Compositions formulated for parenteral administration may be injected by bolus injection or by timed bolus injection, or may be administered by continuous infusion.
Dosage forms for topical or transdermal administration of a compound of the invention include ointments, powders, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and any required preservatives or buffers as may be required. Ophthalmic formulations, ear drops and eye drops are also considered to be within the scope of the present invention. Furthermore, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms may be prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
In some embodiments, the present invention provides pharmaceutical compositions of the compounds and other excipients described herein. In some other embodiments, the present invention provides pharmaceutical compositions of the compound of formula (a) and other excipients described herein.
In some embodiments, the pharmaceutical formulations of the present invention provide stable solid oral dosage forms of the active compounds by using excipients having low water or low water content and prepared using dry or non-aqueous formulation methods.
Methods of treating diseases
The present invention provides a method for preventing and/or treating a proteasome-mediated disorder (e.g., cancer, cardiovascular disease, inflammation, immunological disease, kidney disease, angiogenesis, or prostate), comprising the steps of: administering to a subject in need of treatment a compound of the present invention, or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention. As used herein, the term "proteasome-mediated disorder" includes any disorder, disease or condition caused by or characterized by or requiring proteasome activity. The term "proteasome-mediated disorder" also includes any disorder, disease or condition in which inhibition of proteasome activity is beneficial.
For example, the invention compoundsThe substances and pharmaceutical compositions thereof are useful for the treatment of proteins regulated by proteasome activity (e.g., NFkB, p27kip、p21WAF/CIPI、p53) The condition mediated thereby. Associated disorders include inflammatory disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, asthma, Chronic Obstructive Pulmonary Disease (COPD), osteoarthritis, dermatological disorders (e.g., atopic dermatitis, psoriasis)), vascular proliferative disorders (e.g., atherosclerosis, restenosis), proliferative ocular disorders (e.g., diabetic retinopathy), benign proliferative disorders (e.g., hemangioma), autoimmune diseases (e.g., multiple sclerosis, tissue and organ rejection), and inflammation associated with infection (e.g., immune response), neurodegenerative disorders (e.g., alzheimer's disease, parkinson's disease, motor neuron disease, neuropathic pain, triplet repeat disorders, astrocytomas and neurodegeneration due to alcoholic liver disease), ischemic injury (e.g., stroke), and cachexia (e.g., with various physiological and pathological conditions (e.g., nerve injury, ischemia, stroke, cachexia, and other pathological conditions including diabetes, and other diseases including diabetes, and other diseases including various physiological and pathological conditions including diabetes, and other diseases including various types of diabetes, including various types including diabetes, and other types including diabetes, including various types of diabetes, and other types of diabetes, including various types including diabetes, including various types including diabetes, and the type including diabetes, and for example, including diabetes, and the type of diabetes, including diabetes, and the like, Fasting, fever, acidosis, HIV infection, cancer affliction, and certain endocrinopathies).
The compounds and pharmaceutical compositions of the invention are particularly useful in the treatment of cancer. As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissues, and/or the ability to establish a neoplasm at an ectopic site. The term cancer includes, but is not limited to, solid tumors and blood-borne tumors. The term cancer encompasses diseases of the skin, tissue, organs, bone, cartilage, blood and blood vessels. The term cancer further encompasses primary and metastatic cancers.
Non-limiting examples of solid tumors that can be treated with the disclosed proteasome inhibitors or pharmaceutical compositions include multiple myeloma, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer (including metastatic breast cancer), prostate cancer (including androgen-dependent and androgen-independent prostate cancer), renal cancer (including metastatic renal cell carcinoma), hepatocellular carcinoma, lung cancer (including non-small cell lung cancer, bronchioloalveolar cancer, and lung adenocarcinoma, ovarian cancer (including progressive epithelial or primary peritoneal cancer), cervical cancer, gastric cancer, head and neck cancer (including squamous cell carcinoma of the head and neck, melanoma, neuroendocrine cancer (including metastatic neuroendocrine tumors), brain tumors (including glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma, bone cancer, and soft tissue sarcoma.
Non-limiting examples of hematological malignancies that can be treated with the proteasome inhibitors or pharmaceutical compositions disclosed include the dosage form myeloid leukemia (AML); chronic Myelogenous Leukemia (CML), including accelerated CML and CML catastrophe (CML-BP); acute Lymphoblastic Leukemia (ALL); chronic Lymphocytic Leukemia (CLL); hodgkin's Disease (HD); non-hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma; b cell lymphoma; t cell lymphoma; multiple myeloma; waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS) including Refractory Anemia (RA), refractory anemia with sideroblasts (RARS), refractory anemia with hypercellularity (RAEB) and transitional RAEB (RAEB-T); and myeloproliferative syndromes.
In certain embodiments, the compounds or pharmaceutical compositions of the invention are used to treat a patient having, or at risk of developing, or experiencing, a recurrence of a cancer selected from the group consisting of multiple myeloma and mantle cell lymphoma.
In certain embodiments, the compounds or pharmaceutical compositions of the present invention are administered in conjunction with other therapeutic agents. The other therapeutic agents may also inhibit proteasomes, or operate by different mechanisms. In certain embodiments, the other therapeutic agent is typically administered to a patient suffering from the disease or condition being treated. The proteasome inhibitors of the present invention can be administered with other therapeutic agents in a single dosage form or in separate dosage forms. When administered in separate dosage forms, the other therapeutic agents can be administered prior to, concurrently with, or subsequent to the administration of the proteasome inhibitor of the present invention.
In certain embodiments, the proteasome inhibitor of formula (a) or the pharmaceutical composition of the compound of formula (a) is administered in combination with an anti-cancer agent. As used herein, the term "anti-cancer agent" refers to any agent that is administered to an individual having cancer for the purpose of cancer.
In some embodiments, the compounds of the present invention may be used in combination with drugs for the treatment of cancer, cardiovascular disease, inflammation, immunological disease, renal disease, angiogenesis, and prostate disease. More preferably, the therapeutic agents include, but are not limited to: 5-fluorouracil, AV412, avastin (Avstin, bevacizumab), bexarotene (bexarotene), bortezomib (bortezomib), calcitriol (calcetriol), canertinib (canertinib), capecitabine (capecitabine), carboplatin (carboplatin), celecoxib (celecoxib), cetuximab (cetuximab), CHR-2797, cisplatin (cistatin), dasatinib (dasatinib), digoxin (digoxin), ezastaurin, erlotinib (erlotinib), etoposide (etoposide), everolimus (everolimus), fulvestrant (fulvestrant), gefitinib (gefitinib), 2-difluorocytecoxib (cytecoxib), isocytisine (oxaliplatin), paclitaxel (oxaliplatin), paclitaxel (paclitaxel), paclitaxel (blepharbitonidine), paclitaxel (paclitaxel), paclitaxel (bleomycin), paclitaxel (paclitaxel), paclitaxel (oxaliplatin) PEGylated granulocyte colony stimulating factor (pegfilgrastin), PEGylated alpha-interferon (pegylated alfa-interferon), pemetrexed (pemetrexed), Polyphenon E, satraplatin (satraplatin), sirolimus (sirolimus), sunitinib (sutent), sulindac (sulindac), taxotere (taxotere), temozolomide (temomozolomide), Torrilimus (temsirolimus), TGOI tipifarnib, trastuzumab (trastuzumab), valproic acid (valproic acid), vinflunine (vinflunine), Voloximab, vorosintat, and XL 647.
Examples
The compounds of the present invention can be prepared using the methods disclosed herein and conventional variations apparent in light of the present disclosure as well as methods well known in the art. Conventional well-known synthetic methods may also be used in addition to those taught in the present application. The synthesis of the compounds described herein can be achieved as described in the examples below. If commercially available, the reagents may be purchased commercially, for example, from sahn chemical technology (shanghai) ltd or other chemical suppliers. Unless otherwise indicated, the starting materials for the following reactions are available from commercial sources.
Example 1: synthesis of Compound (A-1)
The synthetic route of compound (A-1) is as follows:
chlorinating the compound (G) to form a compound (F)
Compound G (10.0G, 52.4mmol) and thionyl chloride (60ml) were added to the reactor in this order, the reaction was stirred at 80 ℃ for about 4h, and the reaction was analyzed on a dot plate until the starting material was reacted completely. The reaction solution was cooled to room temperature, and excess thionyl chloride was removed by rotary evaporation under reduced pressure to obtain 10.2g of a liquid product, which was directly fed to the next step.
Acylation of Compound (F) to Compound (E)
Sequentially adding glycine-2, 2-d2(1.65g, 21.5mmol) and sodium hydroxide (3.43g, 85.9mmol) were dissolved in 30ml of THF, and a solution of Compound F (3.0g, 14.3mmol, 8ml) in tetrahydrofuran was added dropwise at 0 ℃ and the reaction was stirred for 1 hour after the addition. After the TLC detection reaction was completed, the PH was adjusted to acidity with diluted hydrochloric acid, a white solid was precipitated, extracted with ethyl acetate (40ml × 2), the organic phase was washed with saturated sodium chloride 2 times, the organic phase was collected, dried over anhydrous sodium sulfate, the solvent was removed, slurried with 20ml of petroleum ether/ethyl acetate (v/v) ═ 10:1 for 1 hour, filtered with suction, and dried to obtain 2.9g of a white solid product with a yield of 81%. LC-MS (APCI) M/z 250.6(M +1)+。
Subjecting compound (E) and compound (D) to peptide coupling reaction to form compound (C)
Compound E (10.0g, 40.0mmol), compound D (15.1g, 40.0mmol), TBTU (12.8g, 40.0mmol) were dissolved in 80ml of anhydrous DMF, and DIPEA (10.3g, 80.0mmol) was added dropwise after cooling to 0 ℃ and the reaction was continued with stirring at low temperature for 1 hour after completion of the addition. After the TLC detection reaction is finished. Adding 100ml of water to quench the reaction, extracting with ethyl acetate (150ml multiplied by 2), combining organic phases, washing the organic phases with 5% sodium chloride for 2 times, saturated salt water for one time, 2% potassium carbonate for 2 times, 1% phosphoric acid for one time, finally washing with saturated salt water, drying with anhydrous sodium sulfate, and spin-drying to obtain 18.5g of white solid product with the yield of 93.2%. LC-MS (APCI) M/z 497.3(M +1)+。
Deprotection of Compound (C) to form Compound (B)
Sequentially adding compound C (6.3g, 12.7mmol) and isobutyl boric acid (3.36g, 32.9mmol) into 80ml of methanol and 80ml of N-hexane for dissolving, adding 1N hydrochloric acid (19ml, 19mmol), stirring at room temperature for reaction for 15 hours, separating a methanol layer after TLC detection reaction, washing three times by using the N-hexane, concentrating most of methanol solution, adding 2N sodium hydroxide (30ml) for salification, washing three times by using dichloromethane, adjusting the pH of an aqueous phase to 2-3 by using concentrated hydrochloric acid, extracting by using dichloromethane (60ml multiplied by 3), combining organic phases, washing by using saturated saline solution, drying the organic phase, spin-drying to obtain a crude product, pulping by using 100ml of N-heptane for 2 hours, performing suction filtration and drying to obtain a white solid product 3.1g, and obtaining the yield: 67%.
Reacting the compound (B) with citric acid to form a compound (A-1)
Compound B (1.0g, 2.75mmol) and citric acid (0.58g, 3.03mmol) were added to 1,4-dioxane (1,4-dioxane) (25ml) solution in sequence, the reaction solution was stirred at 80 ℃ for about 5h, dot-panel analysis was performed until the starting material reaction was complete, the solvent was spun off, ethyl acetate (30ml) was added at room temperature and stirred for 12h to precipitate a solid, which was filtered with suction to give 1.1g of a white solid product in 77% yield. Mp.186-191 ℃, LC-ms (apci) M/z 519.2(M +1)+。1H NMR(400MHz,DMSO)δ12.12(s,2H),10.69(s,1H),9.09(s,1H),7.65(t,J=1.4Hz,1H),7.55(d,J=1.4Hz,2H),2.95–2.51(m,5H),1.66(s,1H),1.22(s,2H),0.86(d,J=6.4Hz,6H),13C NMR(101MHz,DMSO)δ177.73,175.96,170.83,170.48,165.57,136.91,131.62,131.53,131.04,129.03,128.96,76.16,42.99,40.86,39.96,38.20,24.89,23.66,21.38。
Example 2: formation of Compound (A-2)
Adding the compound B (1.0g, 2.75mmol) and citric acid (0.58g, 3.03mmol) into ethyl acetate (25ml) in sequence, stirring and reacting the reaction solution at 70 ℃ for 10 minutes, then closing and heating, naturally cooling to room temperature and stirring for 12 hours, separating out a solid, and performing suction filtration to obtain a white solid product 1.2g, wherein the yield is 84%. Mp.220-224 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。1H NMR(400MHz,DMSO)δ12.12(s,2H),10.69(s,1H),9.09(s,1H),7.65(t,J=1.4Hz,1H),7.55(d,J=1.4Hz,2H),2.95–2.51(m,5H),1.67(s,1H),1.36–1.17(m,2H),0.86(d,J=6.5Hz,6H),13C NMR(101MHz,DMSO)δ177.75,175.91,170.80,170.41,165.58,136.91,131.63,131.53,131.04,129.05,128.96,76.20,42.98,40.89,38.96,38.16,24.90,23.60,21.34。
Compound (A-2) can also be produced by the following method:
the method 2 comprises the following steps: compound B (0.2g, 0.55mmol) and citric acid (0.12g, 0.61mmol) were added to a dichloromethane (15ml) solution in this orderThe reaction solution is stirred and reacted for about 5 hours at the temperature of 45 ℃, the reaction solution is analyzed by a dot-plate method until the raw materials are completely reacted, the solvent is dried in a spinning mode, ethyl acetate is added at the room temperature until all solids are dissolved, the reaction solution is stirred for 12 hours at the room temperature, the solids are separated out and filtered, 0.22g of white solid products are obtained, and the yield is 76%. Mp.220-224 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。
The method 3 comprises the following steps: adding the compound B (0.2g, 0.55mmol) and citric acid (0.12g, 0.61mmol) into tetrahydrofuran (15ml) in sequence, stirring the reaction solution at 65 ℃ for about 5h, performing dot-plate analysis until the raw materials are completely reacted, spin-drying the solvent, adding ethyl acetate at room temperature until all solids are dissolved, stirring at room temperature for 12h, precipitating the solids, and performing suction filtration to obtain 0.24g of a white solid product with the yield of 83%. Mp.222-226 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。
The method 4 comprises the following steps: adding the compound B (0.2g, 0.55mmol) and citric acid (0.12g, 0.61mmol) into acetone (15ml) in sequence, stirring the reaction solution at 60 ℃ for about 5h, performing dot-plate analysis until the raw materials are completely reacted, spin-drying the solvent, adding ethyl acetate at room temperature until all solids are dissolved, stirring at room temperature for 12h, precipitating the solids, and performing suction filtration to obtain 0.21g of a white solid product with the yield of 73%. Mp.220-224 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。
The method 5 comprises the following steps: adding the compound B (0.2g, 0.55mmol) and citric acid (0.12g, 0.61mmol) into methyl tert-butyl ether (15ml) in sequence, stirring the reaction solution at 56 ℃ for about 5h, performing dot-plate analysis until the raw materials are completely reacted, drying the solvent by spinning, adding ethyl acetate at room temperature until all solids are dissolved, stirring at room temperature for 12h, precipitating the solids, and performing suction filtration to obtain 0.24g of a white solid product with the yield of 83%. Mp.222-224 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。
The method 6 comprises the following steps: sequentially adding a compound B (0.2g, 0.55mmol) and citric acid (0.12g, 0.61mmol) into a glycol dimethyl ether (15ml) solution, stirring the reaction solution at 80 ℃ for about 5h, performing dot-plate analysis until the raw materials are completely reacted, spin-drying the solvent, adding ethyl acetate at room temperature until all solids are dissolved, stirring at room temperature for 12h, precipitating the solids, and performing suction filtration to obtain a white solid product0.20g, yield 70%. Mp.220-226 deg.C, LC-MS (APCI) M/z 519.2(M +1)+。
Example 3: crystalline forms of a compound of formula (A)
The crystalline form of compound (a) was analyzed by XRPD, DSC and TGA. XRPD patterns were collected using a PANalytical X' Pert PRO MPD diffractometer using mainly the following experimental setup: the voltage of 40kV, 40mA,the scanning range is 4-40 degrees 2θStep size of 0.02 DEG 2θ. DSC and TGA analyses were performed on NETZSCH STA449F3 STA449F3A-1029-M differential scanning calorimeter-thermogravimetric analyzer using about 3-6 mg of sample at a heating rate of 10 ℃/min over a range of 25 ℃ to 400 ℃.
1. Crystal form I of compound of formula (A-1)
Compound of formula (a-1) crystalline form I was prepared as in example 1, obtaining a crystalline form as an ethyl acetate solvent system. Form I of the compound of formula (A-1) is characterized by XRPD, DSC and TGA. The XRPD pattern is shown in fig. 1, and the XRPD pattern analysis data is shown in table 1. TGA does not show any weight loss below about 50 ℃, about 0.9% weight loss is observed at about 50 ℃ to about 200 ℃, followed by decomposition (figure 2). The DSC thermogram shows a sharp endotherm at about 197.9 ℃ followed by a sharp endotherm at about 249.7 ℃ (fig. 2).
Table 1: XRPD pattern analysis data of compound crystal form I of formula (A-1)
2. Crystal form I of compound of formula (A-2)
Compound of formula (a-2) crystalline form I was prepared as in example 1, obtaining a crystalline form as an ethyl acetate solvent system. Form I of the compound of formula (A-2) is characterized by XRPD, DSC and TGA. The XRPD pattern is shown in fig. 3, and the XRPD pattern analysis data is shown in table 2. TGA does not show any weight loss below about 50 ℃, about 0.9% weight loss is observed at about 50 ℃ to about 200 ℃, followed by decomposition (figure 4). The DSC thermogram shows a sharp endotherm at about 224.6 ℃, 237.0 ℃ followed by a sharp endotherm at about 253.5 ℃ (fig. 4).
Table 2: XRPD pattern analysis data of compound crystal form I of formula (A-2)
Example 4: antiproliferative assay
The in vitro antiproliferative activity of the compounds of the invention on tumor cells cultured in vitro was examined by the MTS method.
Cell line: myeloma cells MM.1s (purchased from American Collection of Standard biologicals (ATCC)) were cultured in RPMI1640 medium containing 10% fetal bovine serum, 100U/ml penicillin and 100. mu.g/ml streptomycin.
Reagents and consumables: RPMI-1640(GIBCO, Cat. No. A10491-01); fetal bovine serum (GIBCO, catalog No. 10099141); 0.25% trypsin-EDTA (GIBCO, cat No. 25200); penicillin-streptomycin; liquid (GIBCO, catalog number 15140- & 122); DMSO (Sigma, cat # D2650); MTS assay kit (Promega, catalog No. G3581), 96-well plate (Corning, catalog No. 3365).
The specific experimental method comprises the following steps:
compound preparation: test compounds were dissolved in DMSO to prepare a 20mM stock solution, which was stored at-20 ℃. Diluted 3-fold with DMSO gradient and 10-fold. When adding medicine, the medicine is diluted 4 times by using cell culture medium.
MTS cell viability assay: cells in the logarithmic growth phase were digested with 0.25% trypsin-EDTA, and 150. mu.l of the compound diluted 4-fold in culture medium was inoculated into a 96-well plate at the optimized density, and 50. mu.l/well (ten concentrations: 100, 33.3, 11.1, 3.70, 1.23, 0.412, 0.137, 0.0457, 0.0152, 0.00508. mu.M were generally selected) was added after 24 hours. Wells to which the same volume of 0.5% DMSO was added served as controls. After the cells were cultured for 72 hours, the MTS measured the cell viability.
The method comprises the following specific operations: adherent cells, medium was discarded and a mixture containing 20. mu.L MTS and 100. mu.l medium was added to each well. The culture was continued for 1 to 4 hours in an incubator and then OD490 was measured using OD650 as a reference. Dose-response curves were generated and IC calculated using GraphPad Prism software50。
When tested in this assay, compound a-1 and compound a-2 each exhibited potent superior inhibitory activity compared to the non-deuterated compounds. The results are given in Table 3 below.
Table 3: in vitro antiproliferative Activity assay of Compounds of formula (A)
Example 5: hepatic microsomal stability assay of Compounds of formula (A)
Microsome experiment: human liver microsomes: 0.5mg/mL, Xenotech; rat liver microsomes: 0.5mg/mL, Xenotech; coenzyme (NADPH/NADH): 1mM, Sigma Life Science; magnesium chloride: 5mM, 100mM phosphate buffer (pH 7.4).
Preparing a stock solution: an amount of the compound of example was weighed out finely and dissolved in DMSO to 5mM each.
Preparation of phosphate buffer (100mM, pH 7.4): 150mL of 0.5M potassium dihydrogenphosphate and 700mL of 0.5M dipotassium hydrogenphosphate solution prepared in advance were mixed, the pH of the mixture was adjusted to 7.4 with the 0.5M dipotassium hydrogenphosphate solution, diluted 5-fold with ultrapure water before use, and magnesium chloride was added to obtain a phosphate buffer solution (100mM) containing 100mM potassium phosphate and 3.3mM magnesium chloride at a pH of 7.4.
NADPH regenerating system solution (containing 6.5mM NADP, 16.5mM G-6-P, 3U/mL G-6-P D, 3.3mM magnesium chloride) was prepared and placed on wet ice before use.
Preparing a stop solution: acetonitrile solution containing 50ng/mL propranolol hydrochloride and 200ng/mL tolbutamide (internal standard). 25057.5 mu L of phosphate buffer solution (pH7.4) is taken to a 50mL centrifuge tube, 812.5 mu L of human liver microsome is respectively added and mixed evenly, and liver microsome dilution liquid with the protein concentration of 0.625mg/mL is obtained. 25057.5 mu L of phosphate buffer (pH7.4) is taken to a 50mL centrifuge tube, 812.5 mu L of SD rat liver microsome is respectively added, and the mixture is mixed evenly to obtain liver microsome dilution with the protein concentration of 0.625 mg/mL.
Incubation of the samples: the stock solutions of the corresponding compounds were diluted to 0.25mM each with an aqueous solution containing 70% acetonitrile, and used as working solutions. 398. mu.L of human liver microsome or rat liver microsome dilutions were added to a 96-well plate (N2), 2. mu.L of 0.25mM working solution was added, and mixed well.
Determination of metabolic stability: 300. mu.L of pre-cooled stop solution was added to each well of a 96-well deep-well plate and placed on ice as a stop plate. The 96-well incubation plate and the NADPH regeneration system are placed in a 37 ℃ water bath box, shaken at 100 rpm and pre-incubated for 5 min. 80. mu.L of the incubation solution was taken out of each well of the incubation plate, added to the stop plate, mixed well, and supplemented with 20. mu.L of NADPH regenerating system solution as a 0min sample. Then 80. mu.L of NADPH regenerating system solution was added to each well of the incubation plate, the reaction was started, and the timer was started. The reaction concentration of the corresponding compound was 1. mu.M, and the protein concentration was 0.5 mg/mL. When the reaction was carried out for 10min, 30 min and 90min, 100. mu.L of each reaction solution was added to the stop plate and vortexed for 3min to terminate the reaction. The stop plates were centrifuged at 5000 Xg for 10min at 4 ℃. And (3) taking 100 mu L of supernatant to a 96-well plate in which 100 mu L of distilled water is added in advance, mixing uniformly, and performing sample analysis by adopting LC-MS/MS.
And (3) data analysis: and detecting peak areas of the corresponding compound and the internal standard through an LC-MS/MS system, and calculating the peak area ratio of the compound to the internal standard. The slope is determined by plotting the natural logarithm of the percentage of compound remaining against time and calculating t according to the following formula1/2And CLintWhere V/M is equal to 1/protein concentration.
The compound of formula (a) of the present invention and the compound Ixazomib, which is a compound without deuteration, were simultaneously tested and compared, and their metabolic stability in human and rat liver microsomes was evaluated. In human and rat liver microsome experiments, the half-lives of the compounds of formula (A-1) and (A-2) were significantly longer than those of Ixazomib, while the clearance was significantly less than that of Ixazomib.
Example 6: pharmacokinetic experiment of rat
6 male Sprague-Dawley rats, 7-8 weeks old, weighing about 210g, were divided into 2 groups of 3 per group and compared for pharmacokinetic differences by intravenous or oral administration of a single dose of the compound (intravenous 0.3 mg/kg; oral 2 mg/kg).
Rats were fed with standard feed and given water. Fasting began 16 hours prior to the experiment. The drug was dissolved with PEG400 and dimethyl sulfoxide. Blood was collected from the orbit at 0.083 hr, 0.25 hr, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr and 24 hr post-dose.
The rats were briefly anesthetized after ether inhalation and 300 μ L of blood was collected from the orbit into a test tube. There was 30 μ L of 1% heparin salt solution in the tube. Before use, the tubes were dried overnight at 60 ℃. After completion of blood collection at the last time point, rats were sacrificed after ether anesthesia.
Immediately after blood collection, the tubes were gently inverted at least 5 times to ensure mixing and then placed on ice. The blood samples were centrifuged at 5000rpm for 5 minutes at 4 ℃ to separate the plasma from the erythrocytes. Pipette 100 μ L of plasma into a clean plastic centrifuge tube, designating the name of the compound and the time point. Plasma was stored at-80 ℃ before analysis. The concentration of the compounds of the invention in plasma was determined by LC-MS/MS. Pharmacokinetic parameters were calculated based on the plasma concentration of each animal at different time points.
Experiments show that the compound has better pharmacokinetic property in animals, so that the compound has better treatment effect. The results are shown in Table 4 below.
Table 4: rat pharmacokinetic experiments with Compounds of formulae (A-1) and (A-2)
Example 7: pharmaceutical composition
The drug of the present invention can take the following pharmaceutical compositions, but is not limited thereto:
pharmaceutical composition 1
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 4 | 1.3 |
Silicified microcrystalline cellulose | 292.4 | 97.5 |
Talcum powder | 0.6 | 0.2 |
Magnesium stearate | 3 | 1 |
Weight of |
300 | 100 |
Pharmaceutical composition 2
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 4 | 1.3 |
Microcrystalline cellulose | 231.8 | 77.8 |
|
60 | 20 |
Silicon dioxide | 1.2 | 0.1 |
Magnesium stearate | 3 | 1 |
Weight of |
300 | 100 |
Pharmaceutical composition 3
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 4 | 1.3 |
Microcrystalline cellulose | 246.8 | 82.3 |
Mannitol | 45 | 15 |
Talcum powder | 1.2 | 0.4 |
Magnesium stearate | 3 | 1 |
Weight of |
300 | 100 |
Pharmaceutical composition 4
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 3 | 1.5 |
|
150 | 75 |
Corn starch | 45 | 22.5 |
Magnesium stearate | 2 | 1 |
Weight of |
200 | 100 |
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 3 | 1.5 |
Mannitol | 120 | 60 |
Lactose | 45 | 37.5 |
Magnesium stearate | 2 | 1 |
Weight of |
200 | 100 |
Pharmaceutical composition 6
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 3 | 1.5 |
|
100 | 50 |
Microcrystalline cellulose | 95 | 47.5 |
Magnesium stearate | 2 | 1 |
Weight of |
200 | 100 |
Pharmaceutical composition 7
Pharmaceutical composition 8
Composition (I) | Dosage per unit dose (mg) | Amount (% w/w or w/w) |
A compound of the formula (A) | 2.3 | 1.15 |
Silicified microcrystalline cellulose | 155 | 77.5 |
|
40 | 20 |
Talcum powder | 0.7 | 0.35 |
Magnesium stearate | 2 | 1 |
Weight of |
200 | 100 |
The medicine composition is mixed homogeneously in certain proportion and packed into opaque white gelatin capsule.
In this example, "the compound of the formula (A)" includes the compound (A-1) and the compound (A-2).
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
In summary, the present invention relates to the following technical solutions:
1. a process for preparing a compound of formula (a) or a crystalline form thereof:
wherein n and m are independently selected from 0 or 1; and n and m are different from each other,
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a):
b) optionally crystallizing the compound of formula (a).
2. The process according to claim 1, wherein the solvent of step a) is dioxane and the product compound of formula (a) is a compound of formula (a-1)
3. The process according to claim 2, wherein the solvent of step a) is 1, 4-dioxane.
4. The process according to claim 2, wherein the reaction temperature of step a) is from 40 ℃ to 101.1 ℃.
5. The process according to claim 2, wherein the reaction temperature in step a) is 80 ℃.
6. The process according to any of claims 2 to 5, wherein step a) is adding the compound of formula (B) and citric acid to a solvent and the reaction is stirred at 80 ℃ until the starting materials react completely.
7. The process according to any of claims 2-6, wherein step b) the solvent of step a) is removed and ethyl acetate is added at room temperature and stirred until a solid precipitates.
8. The method according to claim 7, wherein in step b), ethyl acetate is added at room temperature and stirred for 12h, and a solid is precipitated and filtered.
9. The process of claim 1, wherein the reaction solvent of step a) comprises methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, methyl tert-butyl ether and mixtures thereof,
the product compound of formula (A) is a compound of formula (A-2)
10. The process according to claim 9, wherein the reaction temperature of step a) is from 40 ℃ to 80 ℃.
11. The process according to any one of claims 9 to 10, wherein step a) is adding the compound of formula (B) and citric acid to a solvent, and stirring the reaction until the starting materials react completely.
12. The process according to any of claims 9-11, wherein step b) the solvent of step a) is removed and ethyl acetate is added at room temperature and stirred until a solid precipitates.
13. The process according to claim 9, wherein the solvent of step a) is ethyl acetate.
14. The process according to claim 13, wherein the reaction temperature in step a) is 70 ℃.
15. The process of claim 13, wherein the compound of formula (B) and citric acid are added to a solvent, stirred and reacted at 70 ℃ for 10 minutes, cooled to room temperature and stirred until a solid precipitates.
16. The method according to claim 12 or 15, wherein the temperature is reduced to room temperature and stirred for 12h, and a solid is precipitated and filtered.
17. A compound of formula (a) or a crystal thereof prepared by the process of any one of claims 1 to 16.
18. A compound of formula (A-1) in crystalline form I,
19. a compound of formula (A-1) in crystalline form I,
characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 16.137, 17.56, 19.001, 20.201, 24.88, 25.358 degrees 2 theta + -0.2 degrees 2 theta, using a wavelength on a diffractometerCu-Ka radiation assay of (1).
20. Compound of formula (a-1) crystalline form I according to technical scheme 19, characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.599, 14.80, 16.137, 17.56, 19.001, 20.201, 21.02, 24.88, 25.358 DEG 2 theta +/-0.2 DEG 2 theta, which is used on a diffractometer at a wavelength ofCu-Ka radiation assay of (1).
21. Compound of formula (a-1) crystalline form I according to technical scheme 19, characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1).
22. A compound of formula (a-1) crystalline form I according to claim 19, wherein the diffractogram is substantially as shown in figure 1.
23. Compound of formula (a-1) crystalline form I according to claim 19, characterized by a Differential Scanning Calorimetry (DSC) curve comprising endotherms at about 197.9 ℃ and about 249.7 ℃.
24. A compound of formula (a-1) crystalline form I according to technical scheme 19, wherein said DSC curve is substantially as shown in figure 2.
25. A compound of formula (A-2) in crystalline form I,
characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.740, 7.517, 11.458, 19.438, 19.801 and 22.262 DEG 2 theta + -0.2 DEG 2 theta, using a wavelength on a diffractometerCu-Ka radiation assay of (1).
26. Compound of formula (a-2) crystalline form I according to technical scheme 25, characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.740, 7.517, 11.458, 12.439, 16.578, 19.438, 19.801, 22.262, and 22.999 ° 2 θ ± 0.2 ° 2 θ, using a wavelength on a diffractometerCu-Ka radiation assay of (1).
27. Compound of formula (a-2) crystalline form I according to technical scheme 25, characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1).
28. A crystalline form I of a compound of formula (a-2) according to claim 25, wherein the diffractogram is substantially as shown in figure 3.
29. A compound of formula (a-2) crystalline form I according to claim 25, characterized by a Differential Scanning Calorimetry (DSC) curve that comprises endotherms at about 224.6 ℃, about 237.0 ℃, and about 253.5 ℃.
30. A compound of formula (a-2) crystalline form I according to technical scheme 25, wherein said DSC curve is substantially as shown in figure 4.
31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (a) or crystals thereof as described in claim 17, a compound of formula (a-1) in claim 18, or a compound of formula (a-1) in any one of claims 19-24, or a compound of formula (a-2) in any one of claims 25-30, in crystalline form I.
32. Use of a compound of formula (a) according to claim 17 or a crystal thereof, a compound of formula (a-1) according to claim 18, or a crystalline form I of a compound of formula (a-1) according to any one of claims 19 to 24, or a crystalline form I of a compound of formula (a-2) according to any one of claims 25 to 30 for the manufacture of a medicament for the treatment and prevention of proteasome-related diseases.
33. Use of a compound of formula (a) according to claim 17 or a crystal thereof, a compound of formula (a-1) according to claim 18, or a crystalline form I of a compound of formula (a-1) according to any one of claims 19 to 24, or a crystalline form I of a compound of formula (a-2) according to any one of claims 25 to 30, in the manufacture of a medicament for the treatment and prevention of cancer, cardiovascular disease, inflammation, immunological disease, kidney disease, angiogenesis or prostate disease.
34. According to the use of claim 33, the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, rectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumor, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
Claims (10)
2. a compound of formula (A-1) in crystalline form I,
characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 16.137, 17.56, 19.001, 20.201, 24.88, 25.358 ° 2 θ ± 0.2 ° 2 θ; preferably, the following peaks are included: 6.361, 8.06, 10.599, 14.80, 16.137, 17.56, 19.001, 20.201, 21.02, 24.88, 25.358 degrees 2 theta plus or minus 0.2 degrees 2 theta; preferably, the following peaks are included: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1); preferably, the diffraction pattern is substantially as shown in figure 1.
3. The compound of formula (a-1) crystalline form I according to claim 2, characterized by a Differential Scanning Calorimetry (DSC) curve comprising endotherms at about 197.9 ℃ and about 249.7 ℃; preferably, the DSC curve is substantially as shown in figure 2.
4. A compound of formula (A-2) in crystalline form I,
characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.740, 7.517, 11.458, 19.438, 19.801 and 22.262 ° 2 θ ± 0.2 ° 2 θ; preferably, the following peaks are included: 5.740, 7.517, 11.458, 12.439, 16.578, 19.438, 19.801, 22.262, and 22.999 ° 2 θ ± 0.2 ° 2 θ; preferably, the following peaks are included: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840 ° 2θ±0.2θ2θUsing a wavelength on a diffractometer ofCu-Ka radiation assay of (1); preferably, the diffraction pattern is substantially as shown in figure 3.
5. The compound of formula (a-2) crystalline form I according to claim 4, characterized by a Differential Scanning Calorimetry (DSC) curve comprising endotherms at about 224.6 ℃, about 237.0 ℃, and about 253.5 ℃; preferably, the DSC curve is substantially as shown in figure 4.
6. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (a-1) according to claim 1, or a compound of formula (a-1) according to any one of claims 2 to 3 in crystalline form I, or a compound of formula (a-2) according to any one of claims 4 to 5 in crystalline form I.
7. Use of a compound of formula (a-1) according to claim 1, or a crystalline form I of a compound of formula (a-1) according to any one of claims 2 to 3, or a crystalline form I of a compound of formula (a-2) according to any one of claims 4 to 5, for the preparation of a medicament for the treatment and prevention of proteasome-related diseases.
8. Use of a compound of formula (a-1) according to claim 1, or a crystalline form I of a compound of formula (a-1) according to any one of claims 2 to 3, or a crystalline form I of a compound of formula (a-2) according to any one of claims 4 to 5, for the preparation of a medicament for the treatment and prevention of cancer, cardiovascular diseases, inflammation, immunological diseases, renal diseases, angiogenesis or prostate diseases.
9. The use of claim 8, wherein the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, rectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumor, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
10. A process for preparing a compound of formula (a-2) or a crystalline form thereof:
the method comprises the following steps:
a) reacting a compound of formula (B) with citric acid to form a compound of formula (a-2), wherein the solvent is selected from the group consisting of methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, methyl tert-butyl ether, and mixtures thereof:
b) optionally crystallizing the compound of formula (A-2);
wherein in the step a), the compound shown in the formula (B) and citric acid are added into a solvent, stirred and reacted for 10 minutes at 70 ℃, cooled to room temperature and stirred until a solid is separated out.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711266694 | 2017-12-05 | ||
CN2017112666943 | 2017-12-05 | ||
CN201811390368.8A CN109251218B (en) | 2017-12-05 | 2018-11-21 | Preparation method and crystal form of substituted boric acid ester compound |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811390368.8A Division CN109251218B (en) | 2017-12-05 | 2018-11-21 | Preparation method and crystal form of substituted boric acid ester compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113603713A true CN113603713A (en) | 2021-11-05 |
Family
ID=65043789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811390368.8A Active CN109251218B (en) | 2017-12-05 | 2018-11-21 | Preparation method and crystal form of substituted boric acid ester compound |
CN202110844510.7A Pending CN113603713A (en) | 2017-12-05 | 2018-11-21 | Preparation method and crystal form of substituted boric acid ester compound |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811390368.8A Active CN109251218B (en) | 2017-12-05 | 2018-11-21 | Preparation method and crystal form of substituted boric acid ester compound |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN109251218B (en) |
WO (1) | WO2019109802A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102066386A (en) * | 2008-06-17 | 2011-05-18 | 米伦纽姆医药公司 | Boronate ester compounds and pharmaceutical compositions thereof |
CN103965114A (en) * | 2013-01-28 | 2014-08-06 | 苏州泽璟生物制药有限公司 | Deuterated phenylamino pyrimidine compound and drug composition containing the same |
CN104817559A (en) * | 2014-01-30 | 2015-08-05 | 苏州泽璟生物制药有限公司 | Deuterated quinazolone compound and medical compositions containing same |
CN106916177A (en) * | 2017-03-23 | 2017-07-04 | 南京师范大学 | A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes |
CN108368134A (en) * | 2016-07-25 | 2018-08-03 | 深圳市塔吉瑞生物医药有限公司 | A kind of substituted boronic acid compounds and the medical composition and its use comprising the compound |
CN108794516A (en) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | Boric acid and boric acid ester compound and its preparation method and application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496259A (en) * | 2015-09-08 | 2017-03-15 | 成都贝斯凯瑞生物科技有限公司 | A kind of boracic intermediate and its application in medical industry |
WO2018133661A1 (en) * | 2017-01-23 | 2018-07-26 | 成都奥璟生物科技有限公司 | Novel boric acid derivative and pharmaceutical composition using same |
-
2018
- 2018-11-21 CN CN201811390368.8A patent/CN109251218B/en active Active
- 2018-11-21 CN CN202110844510.7A patent/CN113603713A/en active Pending
- 2018-11-21 WO PCT/CN2018/116623 patent/WO2019109802A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102066386A (en) * | 2008-06-17 | 2011-05-18 | 米伦纽姆医药公司 | Boronate ester compounds and pharmaceutical compositions thereof |
CN103965114A (en) * | 2013-01-28 | 2014-08-06 | 苏州泽璟生物制药有限公司 | Deuterated phenylamino pyrimidine compound and drug composition containing the same |
CN104817559A (en) * | 2014-01-30 | 2015-08-05 | 苏州泽璟生物制药有限公司 | Deuterated quinazolone compound and medical compositions containing same |
CN108368134A (en) * | 2016-07-25 | 2018-08-03 | 深圳市塔吉瑞生物医药有限公司 | A kind of substituted boronic acid compounds and the medical composition and its use comprising the compound |
CN106916177A (en) * | 2017-03-23 | 2017-07-04 | 南京师范大学 | A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes |
CN108794516A (en) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | Boric acid and boric acid ester compound and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN109251218A (en) | 2019-01-22 |
CN109251218B (en) | 2021-08-24 |
WO2019109802A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014244555B2 (en) | DNA-PK inhibitors | |
CA2761256C (en) | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate | |
CA2671535A1 (en) | Novel crystalline compound useful as glk activator | |
CN112566900A (en) | Immunomodulator, composition and preparation method thereof | |
EP4029865A1 (en) | Novel tricyclic aromatic heterocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
JP2023109924A (en) | Dihydroimidazopyrazinone compound, composition including the compound, and use thereof | |
EP3665176B1 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
EP4143166A1 (en) | Heterocyclic compounds as bet inhibitors | |
US20230042479A1 (en) | New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide | |
CN109251218B (en) | Preparation method and crystal form of substituted boric acid ester compound | |
KR20220008284A (en) | Solid form of diaminopyrimidine compound or hydrate thereof, method for preparing same and use thereof | |
WO2020081917A1 (en) | Βeta-catenin and b-cell lymphoma 9 (bcl9) inhibitors | |
AU2016269359A1 (en) | Sodium salt of uric acid transporter inhibitor and crystalline form thereof | |
AU2019339994A1 (en) | Furo[3,4-b]pyrrole-containing BTK inhibitor | |
EP3697794A1 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
JP7434273B2 (en) | Borate of azetidine derivatives | |
EP1907379A1 (en) | Crystalline forms of (2r-trans)-6-chloro-5ýý4-ý(4-fluorophenyl)methyl¨-2,5-dimethyl-1-piperazinyl¨carbonyl¨-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride | |
CN109438362A (en) | A kind of substituted benzimidazole compound and the composition comprising the compound | |
WO2022112951A1 (en) | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate | |
WO2023202651A1 (en) | Polymorphic forms of glutamine antagonist and uses thereof | |
TWI596098B (en) | Polymorphic forms of icotinib maleate and uses thereof | |
JP2023532217A (en) | Crystal forms of SHP2 inhibitors, compositions thereof, methods of preparation and applications thereof | |
CN111484489A (en) | Amorphous B-RAF kinase dimer inhibitors | |
MXPA02007150A (en) | Crystalline monochlorohydrate of 2,5-dione-3-(1-methyl-1h-indole-3-il)-4-[1- (pyridin-2- ylmethyl)piperidin-4-il]-1h-indole-3-yl]-1h- pyrrole. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |